Role of lung surfactant in respiratory disease: Current knowledge in large animal medicine

Journal of Veterinary Internal Medicine

Volumn 23, Issue 2, 2009, Pages 227-242

  Christmann, U ^a   Buechner Maxwell, V A ^a   Witonsky, S G ^a   Hite, R D ^b  

^a VIRGINIA MARYLAND REGIONAL COLLEGE OF VETERINARY MEDICINE   (United States)

^b WAKE FOREST SCHOOL OF MEDICINE   (United States)

Author keywords

Phospholipid; Surface tension; Surfactant; Surfactant proteins

Indexed keywords

ANIMALIA;

LUNG SURFACTANT;

ANIMAL; ANIMAL DISEASE; METABOLISM; RESPIRATORY TRACT DISEASE; REVIEW; SURFACE TENSION;

ANIMAL DISEASES; ANIMALS; PULMONARY SURFACTANTS; RESPIRATORY TRACT DISEASES; SURFACE TENSION;

EID: 66149093147     PISSN: 08916640     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1939-1676.2008.0269.x     Document Type: Review

References (193)

1. Notter RH. Lung surfactants: Basic science and clinical applications. In: Claude L, ed. Lung Biology in Health and Disease,1st ed. New York: Dekker; 2000:207-248.
2. Frerking I, Gunther A, Seeger W, et al. Pulmonary surfactant: Functions, abnormalities and therapeutic options. Intensive Care Med 2001;27:1699-1717.
3. Griese M. Pulmonary surfactant in health and human lung diseases: State of the art. Eur Respir J 1999;13:1455-1476.
4. Von Neergard K. Neue Auffassungen uber einen Grundbegriff der Atemmechanik; die Retraktionskraft der Lunge, abhangig von der Oberflachenspannung der Alveolen. Z Ges Exp Med 1929; 66:373-394.
5. Pattle RE. Properties, function and origin of the alveolar lining layer. Nature 1955;175:1125-1126.
6. Avery ME, Mead J. Surface properties in relation to atelectasis and hyaline membrane disease. AMA J Dis Child 1959;97:517-523.
7. Rossdale PD, Pattle RE, Mahaffey LW. Respiratory distress in a newborn foal with failure to form lung lining fluid. Nature 1967;215:1498-1499.
8. Mahaffey LW, Rossdale PD. A convulsive syndrome in newborn foals resembling pulmonary syndrome in newborn infants. Lancet 1959;7085:1223-1225.
9. Pattle RE, Rossdale PD, Schock C, et al. The development of the lung and its surfactant in the foal and in other species. J Reprod Fertil Suppl 1975;23:651-657.
10. Clements JA, Avery ME. Lung surfactant and neonatal respiratory distress syndrome. Am J Respir Crit Care Med 1998; 157:S59-S66.
11. Williams MA, Schmidt AR, Carleton CL, et al. Amniotic fluid analysis for ante-partum foetal assessment in the horse. Equine Vet J 1992;24:236-238.
12. Lester GD. Foal Diseases. In: Robinson NE, ed. Current Therapy in Equine Medicine 5. Philadelphia, PA: Saunders; 2003:631-697.
13. Kuroki Y, Voelker DR. Pulmonary surfactant proteins. J Biol Chem 1994;269:25943-25946.
14. Rau GA, Vieten G, Haitsma JJ, et al. Surfactant in newborn compared with adolescent pigs: Adaptation to neonatal respiration. Am J Respir Cell Mol Biol 2004;30:694-701.
15. Bernhard W, Hoffmann S, Dombrowsky H, et al. Phosphatidylcholine molecular species in lung surfactant: Composition in relation to respiratory rate and lung development. Am J Respir Cell Mol Biol 2001;25:725-731.
16. Hobo S, Oikawa M, Kuwano A, et al. Effect of transportation on the composition of bronchoalveolar lavage fluid obtained from horses. Am J Vet Res 1997;58:531-534.
17. Hobo S, Yoshihara T, Oikawa M, et al. Surfactant proteins in bronchoalveolar lavage fluid of horses: Assay technique and changes following road transport. Vet Rec 2001;148:74-80.
18. Jahn W. Veranderungen der Surfactantphospholipid-zusammensetzung im Tracheobronchialsekret chronisch lungenkranker Pferde. Pferdeheilkunde 1984;1:155-158.
19. Ito S, Hobo S, Kasashima Y. Bronchoalveolar lavage fluid findings in the atelectatic regions of anesthetized horses. J Vet Med Sci 2003;65:1011-1013.
20. Morrison KE, Slocombe RF, McKane SA, et al. Functional and compositional changes in pulmonary surfactant in response to exercise. Equine Vet J Suppl 1999;30:62-66.
21. Danlois F, Zaltash S, Johansson J, et al. Pulmonary surfactant from healthy Belgian White and Blue and Holstein Friesian calves: Biochemical and biophysical comparison. Vet J 2003;165:65-72.
22. Christmann U, Welles EG, Waldridge BM, et al. Abnormalities in lung surfactant in horses clinically affected with recurrent airway obstruction (RAO). J Vet Intern Med 2008;22:1452-1455.
23. Danlois F, Zaltash S, Johansson J, et al. Very low surfactant protein C contents in newborn Belgian White and Blue calves with respiratory distress syndrome. Biochem J 2000;351:779-787.
24. Wright JR. Clearance and recycling of pulmonary surfactant. Am J Physiol 1990;259:L1-L12.
25. Bernhard W, Haagsman HP, Tschernig T, et al. Conductive airway surfactant: Surface-tension function, biochemical composition, and possible alveolar origin. Am J Respir Cell Mol Biol 1997;17:41-50.
26. Field NT, Gilbert WM. Current status of amniotic fluid tests of fetal maturity. Clin Obstet Gynecol 1997;40:366-386.
27. Wright JR. Immunoregulatory functions of surfactant proteins. Nat Rev Immunol 2005;5:58-68.
28. Rubio S, Lacaze-Masmonteil T, Chailley-Heu B, et al. Pulmonary surfactant protein A (SP-A) is expressed by epithelial cells of small and large intestine. J Biol Chem 1995;270:12162-12169.
29. Madsen J, Kliem A, Tornoe I, et al. Localization of lung surfactant protein D on mucosal surfaces in human tissues. J Immunol 2000;164:5866-5870.
30. Leth-Larsen R, Floridon C, Nielsen O, et al. Surfactant protein D in the female genital tract. Mol Hum Reprod 2004; 10:149-154.
31. Sano H, Kuroki Y. The lung collectins, SP-A and SP-D, modulate pulmonary innate immunity. Mol Immunol 2005;42:279-287.
32. Wright JR. Immunomodulatory functions of surfactant. Physiol Rev 1997;77:931-962.
33. Weaver TE, Conkright JJ. Function of surfactant proteins B and C. Annu Rev Physiol 2001;63:555-578.
34. Tokieda K, Whitsett JA, Clark JC, et al. Pulmonary dysfunction in neonatal SP-B-deficient mice. Am J Physiol 1997;273:L875-L882.
35. Nogee LM, Garnier G, Dietz HC, et al. A mutation in the surfactant protein B gene responsible for fatal neonatal respiratory disease in multiple kindreds. J Clin Invest 1994;93:1860-1863.
36. Whitsett JA, Weaver TE. Hydrophobic surfactant proteins in lung function and disease. N Engl J Med 2002;347:2141-2148.
37. Orgeig S, Daniels CB, Johnston SD, et al. The pattern of surfactant cholesterol during vertebrate evolution and development: Does ontogeny recapitulate phylogeny? Reprod Fertil Dev 2003;15:55-73.
38. Keating E, Rahman L, Francis J, et al. Effect of cholesterol on the biophysical and physiological properties of a clinical pulmonary surfactant. Biophys J 2007;93:1391-1401.
39. West JB. Mechanics of breathing. In: Sun B, ed. Respiratory Physiology, the Essentials. Philadelphia, PA: Lippincott Williams and Wilkins; 2005:93-120.
40. Macklem PT, Proctor DF, Hogg JC. The stability of peripheral airways. Respir Physiol 1970;8:191-203.
41. Liu MY, Wang LM, Li E, et al. Pulmonary surfactant will secure free airflow through a narrow tube. J Appl Physiol 1991; 71:742-748.
42. Enhorning G, Duffy LC, Welliver RC. Pulmonary surfactant maintains patency of conducting airways in the rat. Am J Respir Crit Care Med 1995;151:554-556.
43. Hills BA, Chen Y. Suppression of neural activity of bronchial irritant receptors by surface-active phospholipid in comparison with topical drugs commonly prescribed for asthma. Clin Exp Allergy 2000;30:1266-1274.
44. De Sanctis GT, Tomkiewicz RP, Rubin BK, et al. Exogenous surfactant enhances mucociliary clearance in the anaesthetized dog. Eur Respir J 1994;7:1616-1621.
45. Koetzler R, Saifeddine M, Yu Z, et al. Surfactant as an air-way smooth muscle relaxant. Am J Respir Cell Mol Biol 2006; 34:609-615.
46. Meyer KC, Zimmerman JJ. Inflammation and surfactant. Paediatr Respir Rev 2002;3:308-314.
47. Wright JR. Host defense functions of pulmonary surfactant. Biol Neonate 2004;85:326-332.
48. Wright JR. Pulmonary surfactant: A front line of lung host defense. J Clin Invest 2003;111:1453-1455.
49. Chiba H, Pattanajitvilai S, Evans AJ, et al. Human surfactant protein D (SP-D) binds Mycoplasma pneumoniae by high affinity interactions with lipids. J Biol Chem 2002;277:20379-20385.
50. Ferguson JS, Voelker DR, McCormack FX, et al. Surfactant protein D binds to Mycobacterium tuberculosis bacilli and lipoarabinomannan via carbohydrate[ndash]lectin interactions resulting in reduced phagocytosis of the bacteria by macrophages. J Immunol 1999;163:312-321.
51. Ferguson JS, Voelker DR, Ufnar JA, et al. Surfactant protein D inhibition of human macrophage uptake of Mycobacterium tuberculosis is independent of bacterial agglutination. J Immunol 2002;168:1309-1314.
52. McNeely TB, Coonrod JD. Aggregation and opsonization of type A but not type B Hemophilus influenzae by surfactant protein A. Am J Respir Cell Mol Biol 1994;11:114-122.
53. Holmskov U, Thiel S, Jensenius JC. Collectins and ficolins: Humoral lectins of the innate immune defense. Annu Rev Immunol 2003;21:547-578.
54. Matalon S, Wright JR. Surfactant proteins and inflammation: The yin and the yang. Am J Respir Cell Mol Biol 2004;31:585-586.
55. Wu H. Surfactant proteins A and D inhibit the growth of Gram-negative bacteria by increasing membrane permeability. J Clin Invest 2003;111:1589-1602.
56. Schagat TL, Wofford JA, Wright JR. Surfactant protein A enhances alveolar macrophage phagocytosis of apoptotic neutrophils. J Immunol 2001;166:2727-2733.
57. Reidy MF, Wright JR. Surfactant protein A enhances apoptotic cell uptake and TGF-beta1 release by inflammatory alveolar macrophages. Am J Physiol Lung Cell Mol Physiol 2003;285: L854-L861.
58. Wilsher ML, Hughes DA, Haslam PL. Immunoregulatory properties of pulmonary surfactant: Effect of lung lining fluid on proliferation of human blood lymphocytes. Thorax 1988;43:354-359.
59. Chao W, Spragg RG, Smith RM. Inhibitory effect of porcine surfactant on the respiratory burst oxidase in human neutrophils. Attenuation of p47phox and p67phox membrane translocation as the mechanism. J Clin Invest 1995;96:2654-2660.
60. Wu YZ, Medjane S, Chabot S, et al. Surfactant protein-A and phosphatidylglycerol suppress type IIA phospholipase A2 synthesis via nuclear factor-kappaB. Am J Respir Crit Care Med 2003;168:692-699.
61. Baritussio A. Lung surfactant, asthma, and allergens: A story in evolution. Am J Respir Crit Care Med 2004;169:550-551.
62. Veldhuizen R, Possmayer F. Phospholipid metabolism in lung surfactant. Subcell Biochem 2004;37:359-388.
63. Putman E, Creuwels LAJM, Van Golde LM, et al. Surface properties, morphology and protein composition of pulmonary surfactant subtypes. Biochem J 1996;320:599-605.
64. Veldhuizen RAW, Yao LY, Lewis J. An examination of the different variables affecting surfactant aggregate conversion in vitro. Exp Lung Res 1999;25:127-141.
65. Zhang L, Whitsett JA. Molecular basis for surfactant function in ARDS. In: Wong HR, Shanley TP, eds. Molecular Biology of Acute Lung Injury, 1st ed. Boston: Kluwer Academic Publishers; 2001:177-192.
66. Veldhuizen RA, McCaig LA, Akino T, et al. Pulmonary surfactant subfractions in patients with the acute respiratory distress syndrome. Am J Respir Crit Care Med 1995;152:1867-1871.
67. Ingenito EP, Mora R, Mark L. Pivotal role of anionic phospholipids in determining dynamic behavior of lung surfactant. Am J Respir Crit Care Med 2000;161:831-838.
68. Rodriguez-Capote K, Nag K, Schurch S, et al. Surfactant protein interactions with neutral and acidic phospholipid films. Am J Physiol Lung Cell Mol Physiol 2001;281:L231-L242.
69. Perez-Gil J, Keough KM. Interfacial properties of surfactant proteins. Biochim Biophys Acta 1998;1408:203-217.
70. Enhorning G, Holm BA. Disruption of pulmonary surfactant's aibility to maintain openness of a narrow tube. J Appl Physiol 1993;74:2922-2927.
71. Hirche TO, Crouch EC, Espinola M, et al. Neutrophil serine proteinases inactivate surfactant protein D by cleaving within a conserved subregion of the carbohydrate recognition domain. J Biol Chem 2004;279:27688-27698.
72. 2 and eosinophil lysophospholipases causes surfactant dysfunction. Chest Suppl 2003;123:355S.
73. Seeds MC, Bowton DL, Hite RD, et al. Human eosinophil group IID secretory phospholipase A2 causes surfactant dysfunction. Chest 2003;123:376S-377S.
74. Sweet D, Bevilacqua G, Carnielli V, et al. European consensus guidelines on the management of neonatal respiratory distress syndrome. J Perinat Med 2007;35:175-186.
75. Grenache DG, Gronowski AM. Fetal lung maturity. Clin Biochem 2006;39:1-10.
76. Kobzig L, Schoen FJ. The lung. In: Cotran RS, Kumar V, Collins T, eds. Pathologic Basis of Disease, 6th ed. Philadelphia, PA: WB Saunders; 1999:673-734.
77. Hamvas A, Nogee L, Mallory GB, et al. Lung transplantation for treatment of infants with surfactant protein B deficiency. J Pediatr 1997;130:231-239.
78. Tokieda K, Whitsett JA, Clark JC, et al. Pulmonary dys-function in neonatal SP-B-deficient mice. Am J Physiol 1997;273: L875-L882.
79. deMello DE, Heyman S, Phelps DS, et al. Ultrastructure of lung in surfactant protein B deficiency. Am J Respir Cell Mol Biol 1994;11:230-239.
80. Thompson MW. Surfactant protein B deficiency: Insights into surfactant function through clinical surfactant protein deficiency. Am J Med Sci 2001;321:26-32.
81. Matthay MA, Zimmerman GA. Acute lung injury and the acute respiratory distress syndrome: Four decades of inquiry into pathogenesis and rational management. Am J Respir Cell Mol Biol 2005;33:319-327.
82. Ware LB, Matthay MA. The acute respiratory distress syndrome. N Engl J Med 2000;342:1334-1349.
83. Gunther A, Ruppert C, Schmidt R, et al. Surfactant alteration and replacement in acute respiratory distress syndrome. Respir Res 2001;2:353-364.
84. Davidson WJ, Dorscheid D, Spragg R, et al. Exogenous pulmonary surfactant for the treatment of adult patients with acute respiratory distress syndrome: Results of a meta-analysis. Crit Care 2006;10: R41, 1-9.
85. Bernard GR, Artigas A, Brigham KL, et al. Report of the American-European consensus conference on acute respiratory distress syndrome: Definitions, mechanisms, relevant outcomes, and clinical trial coordination. Consensus Committee. J Crit Care 1994;9:72-81.
86. Schmidt R, Markart P, Ruppert C, et al. Time-dependent changes in pulmonary surfactant function and composition in acute respiratory distress syndrome due to pneumonia or aspiration. Respir Res 2007;8:55, 1-11.
87. Gunther A, Siebert C, Schmidt R, et al. Surfactant alterations in severe pneumonia, acute respiratory distress syndrome, and cardiogenic lung edema. Am J Respir Crit Care Med 1996;153: 176-184.
88. Gregory TJ, Longmore WJ, Moxley MA, et al. Surfactant chemical composition and biophysical activity in acute respiratory distress syndrome. J Clin Invest 1991;88:1976-1981.
89. Hallman M, Spragg R, Harrell JH, et al. Evidence of lung surfactant abnormality in respiratory failure. Study of bronchoalveolar lavage phospholipids, surface activity, phospholipase activity, and plasma myoinositol. J Clin Invest 1982;70:673-683.
90. Pison U, Obertacke U, Brand M, et al. Altered pulmonary surfactant in uncomplicated and septicemia-complicated courses of acute respiratory failure. J Trauma 1990;30:19-26.
91. Pison U, Seeger W, Buchhorn R, et al. Surfactant abnormalities in patients with respiratory failure after multiple trauma. Am Rev Respir Dis 1989;140:1033-1039.
92. Lewis JF, Brackenbury A. Role of exogenous surfactant in acute lung injury. Crit Care Med 2003;31:S324-S328.
93. Kroegel C, Forster M. Pathogenetische Grundlagen des Asthma Bronchiale. In: Kroegel C, ed. Asthma Bronchiale, 2nd ed. Stuttgart: Georg Thieme Verlag; 2002:33-71.
94. Kurashima K, Fujimura M, Matsuda T, et al. Surface activity of sputum from acute asthmatic patients. Am J Respir Crit Care Med 1997;155:1254-1259.
95. Jarjour NN, Enhorning G. Antigen-induced airway inflammation in atopic subjects generates dysfunction of pulmonary surfactant. Am J Respir Crit Care Med 1999;160:336-341.
96. Hohlfeld JM, Ahlf K, Enhorning G, et al. Dysfunction of pulmonary surfactant in asthmatics after segmental allergen challenge. Am J Respir Crit Care Med 1999;159:1803-1809.
97. Heeley EL, Hohlfeld JM, Krug N, et al. Phospholipid molecular species of bronchoalveolar lavage fluid after local allergen challenge in asthma. Am J Physiol Lung Cell Mol Physiol 2000;278: L305-L311.
98. Wright SM, Hockey PM, Enhorning G, et al. Altered airway surfactant phospholipid composition and reduced lung function in asthma. J Appl Physiol 2000;89:1283-1292.
99. Hite RD, Seeds MC, Bowton DL, et al. Surfactant phospholipid changes after antigen challenge: A role for phosphatidylglycerol in dysfunction. Am J Physiol Lung Cell Mol Physiol 2005;288:L610-L617.
100. Hite RD, Seeds MC, Safta AM, et al. Lysophospholipid generation and phosphatidylglycerol depletion in phospholipase A(2)-mediated surfactant dysfunction. Am J Physiol Lung Cell Mol Physiol 2005;288:L618-L624.
101. Hohlfeld JM, Schmiedl A, Erpenbeck VJ, et al. Eosinophil cationic protein alters pulmonary surfactant structure and function in asthma. J Allergy Clin Immunol 2004;113:496-502.
102. Hohlfeld JM, Erpenbeck VJ, Krug N. Surfactant proteins SP-A and SP-D as modulators of the allergic inflammation in asthma. Pathobiology 2002;70:287-292.
103. van de Graaf EA, Jansen HM, Lutter R, et al. Surfactant protein A in bronchoalveolar lavage fluid. J Lab Clin Med 1992;120:252-263.
104. Cheng G, Ueda T, Numao T, et al. Increased levels of surfactant protein A and D in bronchoalveolar lavage fluids in patients with bronchial asthma. Eur Respir J 2000;16:831-835.
105. Kurashima K, Ogawa H, Ohka T, et al. A pilot study of surfactant inhalation in the treatment of asthmatic attack. Arerugi 1991;40:160-163.
106. Babu KS, Woodcock DA, Smith SE, et al. Inhaled synthetic surfactant abolishes the early allergen-induced response in asthma. Eur Respir J 2003;21:1046-1049.
107. Ashwood ER. Standards of laboratory practice: Evaluation of fetal lung maturity. National Academy of Clinical Biochemistry. Clin Chem 1997;43:211-214.
108. Ventolini G, Neiger R, Hood D, et al. Update on assessment of fetal lung maturity. J Obstet Gynaecol 2005;25: 535-538.
109. Fujiwara T, Maeta H, Chida S, et al. Artificial surfactant therapy in hyaline-membrane disease. Lancet 1980;1:55-59.
110. Jobe AH. Pulmonary surfactant therapy. N Engl J Med 1993;328:861-868.
111. Jobe AH. Which surfactant for treatment of respiratory-distress syndrome. Lancet 2000;355:1380-1381.
112. Bernhard W, Mottaghian J, Gebert A, et al. Commercial versus native surfactants. Surface activity, molecular components, and the effect of calcium. Am J Respir Crit Care Med 2000;162: 1524-1533.
113. Lachmann B. Surfactant Replacement Therapy in Neonatal and Adult Respiratory Distress Syndrome, 1st ed. Berlin: Springer-Verlag; 1987.
114. Yu S, Harding PG, Smith N, et al. Bovine pulmonary surfactant: Chemical composition and physical properties. Lipids 1983;18:522-529.
115. Hall SB, Wang Z, Notter RH. Separation of subfractions of the hydrophobic components of calf lung surfactant. J Lipid Res 1994;35:1386-1394.
116. Body DR. The phospholipid composition of pig lung surfactant. Lipids 1971;6:625-629.
117. Kahn MC, Anderson GJ, Anyan WR, et al. Phosphatidylcholine molecular species of calf lung surfactant. Am J Physiol 1995;269:L567-L573.
118. Christmann U, Livesey LC, Taintor JS, et al. Lung surfactant function and composition in neonatal foals and adult horses. J Vet Intern Med 2006;20:1402-1407.
119. Muellenbach RM, Kredel M, Said HM, et al. High-frequency oscillatory ventilation reduces lung inflammation: A large-animal 24-h model of respiratory distress. Intensive Care Med 2007;33:1423-1433.
120. Batchinsky AI, Martini DK, Jordan BS, et al. Acute respiratory distress syndrome secondary to inhalation of chlorine gas in sheep. J Trauma 2006;60:944-956; discussion 956-957.
121. Nieman GF, Gatto LA, Paskanik AM, et al. Surfactant replacement in the treatment of sepsis-induced adult respiratory distress syndrome in pigs. Crit Care Med 1996;24:1025-1033.
122. Eigenmann UJ, Schoon HA, Jahn D, et al. Neonatal respiratory distress syndrome in the calf. Vet Rec 1984;114:141-144.
123. Vestweber JG. Respiratory problems of newborn calves. Vet Clin North Am Food Anim Pract 1997;13:411-424.
124. Pirie HM, Selman IE. Acute respiratory distress syndrome in a premature calf. Vet Rec 1969;85:293-294.
125. Hill JR, Chavatte P. Pregnancy and neonatal care of cloned animals. In: Cibelli JB, ed. Principles of Cloning. Amsterdam: Academic Press; 2002:247-262.
126. Hill JR, Roussel AJ, Cibelli JB, et al. Clinical and pathologic features of cloned transgenic calves and fetuses (13 case studies). Theriogenology 1999;51:1451-1465.
127. Fecteau ME, Palmer JE, Wilkins PA. Neonatal care of high-risk cloned and transgenic calves. Vet Clin North Am Equine Pract 2005;21:637-653.
128. Zaremba W, Grunert E, Aurich JE. Prophylaxis of respiratory distress syndrome in premature calves by administration of dexamethasone or a prostaglandin F2 alpha analogue to their dams before parturition. Am J Vet Res 1997;58:404-407.
129. Buczinski SM, Fecteau G, Lefebvre RC, et al. Fetal well-being assessment in bovine near-term gestations: Current knowledge and future perspectives arising from comparative medicine. Can Vet J 2007;48:178-183.
130. Gordon I. Reproductive Technologies in Farm Animals. Wallingford, UK: CABI Publishing; 2004.
131. Kordts E, Jochle W. Induced parturition in dairy cattle: A comparison of a corticoid (flumethasone) and a prostaglandin (PGF2a) in different age groups. Theriogenology 1975;3:171-178.
132. Lewing FJ, Proulx J, Mapletoft RJ. Induction of parturition in the cow using cloprostenol and dexamethasone in combination. Can Vet J 1985;26:317-322.
133. Baker AA, Copland RS, Rival MD, et al. The induction of parturition as an aid in the management of dystocia in beef herds. Aust Vet J 1988;65:32-33.
134. Johnston NE, Stewart JA. The effect of glucocorticoids and prematurity on absorption of colostral immunoglobulin in the calf. Aust Vet J 1986;63:191-192.
135. Peters AR, Poole DA. Induction of parturition in dairy cows with dexamethasone. Vet Rec 1992;131:576-578.
136. Schmidt M, Sangild PT, Blum JW, et al. Combined ACTH and glucocorticoid treatment improves survival and organ maturation in premature newborn calves. Theriogenology 2004;61:1729-1744.
137. Bo GA, Fernandez M, Barth AD, et al. Reduced incidence of retained placenta with induction of parturition in the cow. Theriogenology 1992;38:45-61.
138. Karapinar T, Dabak M. Treatment of premature calves with clinically diagnosed respiratory distress syndrome. J Vet Intern Med 2008;22:462-466.
139. Ikegami M, Adams FH, Towers B, et al. The quantity of natural surfactant necessary to prevent the respiratory distress syndrome in premature lambs. PediatrRes 1980;14:1082-1085.
140. Hurt H, Kattwinkel J, Roth S. Artificial surfactant treatment in lambs with severe respiratory distress syndrome: A controlled study. J Pediatr 1983;102:450-453.
141. Jobe AH, Newnham JP, Moss TJ, et al. Differential effects of maternal betamethasone and cortisol on lung maturation and growth in fetal sheep. Am J Obstet Gynecol 2003;188:22-28.
142. Lewis JF, Ikegami M, Jobe AH, et al. Aerosolized surfactant treatment of preterm lambs. J Appl Physiol 1991;70:869-876.
143. Jacobs H, Jobe A, Ikegami M, et al. Premature lambs rescued from respiratory failure with natural surfactant: Clinical and biophysical correlates. Pediatr Res 1982;16:424-429.
144. Moss TJ, Mulrooney NP, Nitsos I, et al. Intra-amniotic corticosteroids for preterm lung maturation in sheep. Am J Obstet Gynecol 2003;189:1389-1395.
145. Mescher EJ, Platzker AC, Ballard PL, et al. Ontogeny of tracheal fluid, pulmonary surfactant, and plasma corticoids in the fetal lamb. J Appl Physiol 1975;39:1017-1021.
146. Platzker AC, Kitterman JA, Mescher EJ, et al. Surfactant in the lung and tracheal fluid of the fetal lamb and acceleration of its appearance by dexamethasone. Pediatrics 1975;56:554-561.
147. Benson BJ, Kitterman JA, Clements JA, et al. Changes in phospholipid composition of lung surfactant during development in the fetal lamb. Biochim Biophys Acta 1983;753:83-88.
148. Fujiwara T, Adams FH, Sipos S, et al. "Alveolar" and whole lung phospholipids of the developing fetal lamb lung. Am J Physiol 1968;215:375-382.
149. Meyerholz DK, Kawashima K, Gallup JM, et al. Expression of select immune genes (surfactant proteins A and D, sheep beta defensin 1, and toll-like receptor 4) by respiratory epithelia is developmentally regulated in the preterm neonatal lamb. Dev Comp Immunol 2006;30:1060-1069.
150. Benson BJ, Kitterman JA, Clements JA, et al. Changes in phospholipid composition of lung surfactant during development in the fetal lamb. Biocim Biophys Acta 1983;753:83-88.
151. Ballard PL, Ning Y, Polk D, et al. Glucocorticoid regulation of surfactant components in immature lambs. Am J Physiol 1997;273:L1048-L1057.
152. Jobe AH, Moss TJ, Nitsos I, et al. Betamethasone for lung maturation: Testing dose and formulation in fetal sheep. Am J Obstet Gynecol 2007;197:523-525.
153. Menzies PI. Lambing management and neonatal care. In: Youngquist RS, Threlfall WR, eds. Large Animal Theriogenology. St Louis, MO: Saunders Elsevier; 2007:680-695.
154. Mobini S, Heath AM, Pugh DG. Theriogenology of sheep and goats. In: Pugh DG, ed. Sheep and Goat Medicine. Philadelphia, PA: WB Saunders; 2002:129-186.
155. Hunt ER. Treatment of pregnancy toxaemia in ewes by induction of parturition. Aust Vet J 1976;52: 338-339.
156. Harman EL, Slyter AL. Induction of parturition in the ewe. J Anim Sci 1980;50:391-393.
157. House JK. The peripartum ruminant. In: Smith B, ed. Large Animal Internal Medicine, 4th ed. St Louis, MO: Mosby Elservier; 2009:248-251.
158. Jobe AH. Animal models of antenatal corticosteroids: Clinical implications. Clin Obstet Gynecol 2003;46:174-189.
159. Jobe A, Ikegami M, Glatz T, et al. Duration and characteristics of treatment of premature lambs with natural surfactant. J Clin Invest 1981;67:370-375.
160. Ikegami M, Ueda T, Absolom D, et al. Changes in exogenous surfactant in ventilated preterm lamb lungs. Am Rev Respir Dis 1993;148:837-844.
161. Cummings JJ, Holm BA, Hudak ML, et al. A controlled clinical comparison of four different surfactant preparations in surfactant-deficient preterm lambs. Am Rev Respir Dis 1992;145: 999-1004.
162. Notter RH, Egan EA, Kwong MS, et al. Lung surfactant replacement in premature lambs with extracted lipids from bovine lung lavage: Effects of dose, dispersion technique, and gestational age. Pediatr Res 1985;19:569-577.
163. Meyerholz DK, Ackermann MR. Antimicrobial peptides and surfactant proteins in ruminant respiratory tract disease. Vet Immunol Immunopathol 2005;108:91-96.
164. Grubor B, Gallup JM, Meyerholz DK, et al. Enhanced surfactant protein and defensin mRNA levels and reduced viral replication during parainfluenza virus type 3 pneumonia in neonatal lambs. Clin Diagn Lab Immunol 2004;11:599-607.
165. Grubor B, Gallup JM, Ramirez-Romero R, et al. Surfactant protein D expression in normal and pneumonic ovine lung. Vet Immunol Immunopathol 2004;101:235-242.
166. Bradley R, Wrathall AE. Barker (neonatal respiratory distress) syndrome in the pig: The ultrastructural pathology of the lung. J Pathol 1977;122:145-151.
167. Gibson EA, Blackmore RJ, Wijeratne WV, et al. The "barker" (neonatal respiratory distress) syndrome in the pig: Its occurrence in the field. Vet Rec 1976;98:476-479.
168. Slauson DO. Naturally occurring hyaline membrane disease syndromes in foals and piglets. J Pediatr 1979;95:889-891.
169. Arvidson G, Astedt B, Ekelund L, et al. Surfactant studies in the fetal and neonatal foal. J Reprod Fertil Suppl 1975;23:663-665.
170. Wilkins PA, Otto CM, Baumgardner JE, et al. Acute lung injury and acute respiratory distress syndromes in veterinary medicine: Consensus definitions: The Dorothy Havemeyer Working Group on ALI and ARDS in Veterinary Medicine. J Vet Emergency Crit Care 2007;17:333-339.
171. Paradis MR. Lecithin/sphingomyelin ratios and phosphatidylglycerol in term and premature equine amniotic fluid. Am Vet Med Forum 1987;5:789-792.
172. Williams MA, Goyert NA, Goyert GL, et al. Preliminary report of transabdominal amniocentesis for the determination of pulmonary maturity in an equine population. Equine Vet J 1988;20:457-458.
173. Williams MA, Wallace SS, Tyler JW, et al. Biochemical characteristics of amniotic and allantoic fluid in late gestational mares. Theriogenology 1993;40:1251-1257.
174. Castagnetti C, Mariella J, Serrazanetti GP, et al. Evaluation of lung maturity by amniotic fluid analysis in equine neonate. Theriogenology 2007;67:1455-1462.
175. Rota A, Crisci A, Maranghi L, et al. Concentrations of lamellar bodies and the lecithin/sphingomyelin ratio in equine amniotic fluid at the time of delivery. Vet Res Commun 2006;30: 2003-2006.
176. Alm CC, Sullivan JJ, First NL. The effect of a corticosteroid (dexamethasone), progesterone, oestrogen and prostaglandin F2alpha on gestation length in normal and ovariectomized mares. J Reprod Fertil Suppl 1975;637-640.
177. Jeffcott LB, Rossdale PD. A critical review of current methods for induction of parturition in the mare. Equine Vet J 1977; 9:208-215.
178. Ousey JC, Kolling M, Allen WR. The effects of maternal dexamethasone treatment on gestation length and foal maturation in Thoroughbred mares. Anim Reprod Sci 2006;94:436-438.
179. Rossdale PD. Clinical view of disturbances in equine foetal maturation. Equine Vet J Suppl 1993;14: 3-7.
180. Rossdale PD, McGladdery AJ, Ousey JC, et al. Increase in plasma progestagen concentrations in the mare after foetal injection with CRH, ACTH or betamethasone in late gestation. Equine Vet J 1992;24:347-350.
181. Freeman K, Simmons R, Wilkins PA, et al. Bronchopulmonary dysplasia in neonatal foals. In: 7th ACVIM Forum, San Diego, CA, 1989: 542-545.
182. Mazan M. Non-infectious respiratory problems. In: Paradis MR, ed. Equine Neonatal Medicine. A Case-Based Approach. Philadelphia, PA: Elsevier Saunders; 2006:135-156.
183. Costa LR, Eades SC, Goad ME, et al. Pulmonary surfactant dysfunction and lung maturation in neonatal foals: Therapy, prevention, and prognosis. Compend Contin Pract Vet 2004;26: 460-470.
184. Lester GD. The foal. In: Robinson NE, ed. Current Therapy in Equine Internal Medicine, 4th ed. Philadelphia, PA: Saunders; 1997:581-647.
185. Perry B. The use of bovine derived surfactant in foals with respiratory distress. In: 11th ACVIM Forum, Washington DC, 1993;189-192.
186. Ainsworth DM. Respiratory therapy in foals. In: 19th ACVIM Forum, Denver, CO, 2001;248-249.
187. Hobo S, Ogasawara Y, Kuroki Y, et al. Purification and biochemical characterization of pulmonary surfactant protein A of horses. Am J Vet Res 1999;60:169-173.
188. Hobo S, Ogasawara Y, Kuroki Y, et al. Purification and biochemical characterization of equine pulmonary surfactant protein D. Am J Vet Res 1999;60:368-372.
189. Hospes R, Hospes BI, Reiss I, et al. Molecular biological characterization of equine surfactant protein A. J Vet Med A Physiol Pathol Clin Med 2002;49:497-498.
190. Kankavi O, Ata A, Akif Ciftcioglu M. Surfactant protein A and D in the reproductive tract of stallion. Theriogenology 2006;66:1057-1064.
191. Kankavi O, Ata A, Gungor O. Surfactant proteins A and D in the genital tract of mares. Anim Reprod Sci 2007;98:259-270.
192. Kankavi O, Roberts MS. Detection of surfactant protein A (SP-A) and surfactant protein D (SP-D) in equine synovial fluid with immunoblotting. Can J Vet Res 2004;68:146-149.
193. Humber KA. Near drowning of a gelding. J Am Vet Med Assoc 1988;192:377-378.